# Positron Emission Tomography Study Using 2-[18F]-F-A85380 to Determine α4β2 Neuronal Nicotinic Receptor Occupancy of AZD3480 After Oral Administration to Healthy Male Subjects

> **NCT00686413** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 9 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** AZD3480
- **RADIATION:** 2-[18F]-F-A85380

## Key facts

- **NCT ID:** NCT00686413
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2010-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00686413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00686413, "Positron Emission Tomography Study Using 2-[18F]-F-A85380 to Determine α4β2 Neuronal Nicotinic Receptor Occupancy of AZD3480 After Oral Administration to Healthy Male Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00686413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*